July/August 2022 Newsletter
In This Issue:
  • President's Message
  • Board of Director's Update
  • Public Policy Update
  • R & E Foundation Update
  • Pharmacist Continuing Education Articles
  • Venous Thromboembolism Prophylaxis in Trauma Patients
  • On A Scale of I to X, They’re an XI…A Review of the Newest Anticoagulants, The Factor XIa Inhibitors 
  • Featured Clinical Topics:
  • Aspirin use in primary prevention of CVD: An update
  •  Small Molecule, Large Impact: An Overview of Inclisiran and Its Role in Lipid Management
  • Vericiguat: New Agent for the Treatment of Heart Failure Reduced Ejection Fraction
  • Sodium-Glucose Cotransporter-2 Inhibitor Use in Heart Failure
  • Affiliate Chapter News and Events
  • Upcoming Newsletter Info
President's Message
By Nathan Hanson PharmD, MS, BCPS
It’s Time to Grow!
 
I am so honored to write this first article as President of MSHP. The reason that it’s an honor is that MSHP represents so many exceptional pharmacists, technicians and interns who are leaders across the state. MSHP has had a huge impact on my career and my professional growth, and I am so grateful that I have been given the opportunity to give back in this way.
Board of Director's Update


Board Update
By: Sayo Weihs, PharmD, MBA, BCPS, BCIDP





May
  • Preparing for the new board members to begin
  • Considering business membership similar to other organizations. that allow one membership that covers multiple employees (especially technicians)
  • Discussed legislative day ideas and more collaboration with MPA for next year's legislative day
  • New offering available for webinar: Things not often taught in school: embracing vulnerable population in ambulatory care scheduled June 28th 2PM EST (1 hour CE)
  • Presidential team agreed to sign on to grant which seek to fund a community-based workforce to build COVID-19 vaccine confidence through partner with ASHP for HRSA Grant

June
  • Productive strategic planning meeting, introduced all new Board Members
  • Discussed organizational priorities including website updates, membership, budget 
  • HB-2149 bill was passed and signed by governor this week, the bill goes into effect in August 2022. Public policy committee will discuss and the board to decide on MSHP response next month.  
  • Discussion on revamping website during the strategic planning meeting, website committee to present different options to the presidential group
  •  External audit completed in June, awaiting report from the accounting firm
Public Policy Update
Post-Roe World of Pharmacy 
By: Jennifer A. Tussey PharmD, AAHIVP


After last month’s ruling by the Supreme Court, overturning Roe v. Wade, Governor Mike Parson passed an emergency proclamation enacting a 2019 law, “The Right to Life of the Unborn Child Act,” or 188.017 RSMo. This law now makes abortions in Missouri illegal, except in cases where there is a medical emergency, and the abortion would save the life of the pregnant person. Knowingly performing an abortion on a pregnant person would be considered a Class B Felony and would be punishable by 5-15 years in prison.
Research & Education Foundation Update:
Summer, for the R&E Foundation, is the time that lets us pause, take a step back to review the previous year, and start planning for the next!
Tony Huke, PharmD, BCPS
MSHP R&E Executive Director
Preceptor Development Series 2023
We are now looking for presenters for the Preceptor Development Series for 2023
Potential topics include:
               Tips For New Preceptors
               Formulating Effective Feedback and Interventions
               To Be Determined
 
Want to give a presentation? Have a topic you’re passionate about?  Let us know!
Contact: [email protected]
‌
 
Venous Thromboembolism Prophylaxis in Trauma Patients
Author: Erin Houry, PharmD ,PGY2 Critical Care Pharmacy Resident
Mentors: Bobby Sbertoli, PharmD, BCCCP and Julia Alexander, PharmD, BCPS
Program Number: 2022-05-09
Approved Dates: 08-01-2022 to 02-01-2023
Approved Contact Hours: One Hour(s) (1.0) CE(s)
Learning Objectives
  1. Identify risk factors for venous thromboembolism in trauma patients.
  2. Describe the pathophysiology of coagulopathy in trauma patients.
  3. Compare and contrast the pharmacokinetics of unfractionated heparin and low-molecular weight heparin.
  4. Summarize landmark trials of venous thromboembolism prophylaxis in trauma patients.
  5. Discuss recent guideline updates for venous thromboembolism prophylaxis in trauma patients.
  6. Evaluate the results of relevant clinical studies looking at alternative venous thromboembolism prophylaxis dosing strategies in trauma patients.
  7. List limitations of available studies investigating alternative venous thromboembolism prophylaxis dosing strategies in trauma patients.
  8. Select an appropriate venous thromboembolism prophylactic agent and dose for a specific patient.
On A Scale of I to X, They’re an XI…A Review of the Newest Anticoagulants, The Factor XIa Inhibitors
Author: Rebecca Holmes, PharmD, PGY-1 Pharmacy Resident, Mercy Hospital Springfield 
Mentor: Caleb Gibson, PharmD, Clinical Pharmacist, Mercy Hospital Springfield 
Program Number: 2022-05-08
Approved Dates: 8/1/2022-2/1/2023
Approved Contact Hours: One Hour(s) (1.0) CE(s)
Learning Objectives
  1. Discuss principles of anticoagulation therapy with brief descriptions of the clotting cascade and current anticoagulants. 
  2. Examine the mechanism of action of the new oral anticoagulants.
  3. Summarize the current published literature and discuss the rationale for future larger trials. 
Featured Clinical Topic: Aspirin use in primary prevention of CVD: An update
Author: Michelle Wessling, PharmD
PGY-2 Ambulatory Care Resident, CoxHealth, Springfield, MO

Historically, low-dose aspirin has been recommended for patients at risk for cardiovascular disease (CVD) in the setting of primary and secondary prevention. However, recently the benefit of low-dose aspirin in primary prevention has been called into question for the diabetic and non-diabetic populations. There appears to be some uncertainty regarding the use of low-dose aspirin for primary prevention of cardiovascular events with changes in evidence from studies published in 2018. 
Featured Clinical Topic: Small Molecule, Large Impact: An Overview of Inclisiran and Its Role in Lipid Management
Author: Emilee Broeker, PharmD Candidate 20231
Mentor: Emily Shor, PharmD, BCPS2
1 University of Health Sciences and Pharmacy in St. Louis, 2VA St. Louis Health Care System

Background
With heart disease as the leading cause of death in the United States for men and women, the need for primary prevention strategies in high-risk patients is imperative.1 Over the past several decades, newly developed medication therapies have primarily targeted the reduction of low-density-lipoprotein cholesterol (LDL-C) as a strategy to reduce the risk of atherosclerotic events, such as myocardial infarction.2
Featured Clinical Topic: Vericiguat: New Agent for the Treatment of Heart Failure Reduced Ejection Fraction
Authors: Carli Luebbert, Pharm.D. Candidate and
Andrew Smith, Pharm.D., FCCP, BCCP, BCPS

Nearly 1.75 million Americans today have heart failure with reduced ejection fraction (HFrEF) and this number is expected to increase approximately 25%, to an estimated 2.2 million in 2030.1,2 The rise in prevalence may be attributed to many factors including the aging United States population, increased number of patients with comorbid conditions, and advances in therapeutic cardiac interventions.
Featured Clinical Topic: Sodium-Glucose Cotransporter-2 Inhibitor Use in Heart Failure
Author: Jamie Prashek, PharmD
University of Missouri Health Care Internal Medicine PGY2

Heart failure is a combination of both structural changes and symptoms affecting daily function. A left ventricle ejection fraction (EF) is used to further classify heart failure into reduced, preserved and mid-range. Heart failure with reduced ejection fraction (HFrEF) is defined as an EF of less than or equal to 40%, heart failure with preserved ejection fraction (HFpEF) is an EF greater or equal to 50%, and heart failure mid-range (HFmEF) is an EF between 40-50%.  

Greater Kansas City Society of Health-System Pharmacists (GKCSHP)
 
Meetings and Events:
  • August – General meeting will be August 18th at 5:30 pm at Capital Grille
  • September - Resident Research Day 2022 – Save the Date will be coming soon, planning at this time to have an in-person event

Like us on Facebook: https://www.facebook.com/GKCSHP for updates.

President: Bethany Baker, PharmD, BCPS, BCCCP ([email protected]) 
______________________________________________________________________

Mid-Missouri Society of Health-System Pharmacists (MMSHP)

Like us on Facebook! www.facebook.com/mymmshp/

President: Pamela Sanford, PharmD ([email protected])  
_______________________________________________________________________

Saint Louis Society of Health-System Pharmacists (STLSHP)

Save the Date: September 22, 2022 at 6pm. Join us for a dinner program discussing Telavancin for the treatment of hospital acquired and ventilator associated pneumonia. Location Il Bel Lago 11631 Olive Blvd, Creve Couer, MO 63141.

President: Yvonne Burnett, Pharm.D., BCIDP ([email protected])
_______________________________________________________________________

Southeast Missouri Society of Health-System Pharmacists (SEMSHP)

To join SEMSHP: http://moshp.org/join-us

President: Ashley McCormick, PharmD, BCPS ([email protected])  
Upcoming Newsletter Info
Upcoming Featured Clinical Topics:
  • Sept/Oct 2022: Special Populations (Geriatrics, Pediatrics, Women’s/Men’s Health)/Transitions of Care 
  • Nov/Dec 2022: ID/Vaccines
  • Jan/Feb 2023: Endocrinology/Obesity Management
  • March/April 2023: Psychiatry/Pain/Substance Use Disorder
  •  May/Jun 2023: Critical Care/Pulmonary/Emergency Medicine
  • July/August 2023: Cardiology/Anticoagulation
Submit to: Sara Lingow
Newsletter Submission Deadlines:
  • Sept/Oct 2022: Due August 22
  • Nov/Dec 2022: Due October 24
  • Jan/Feb 2023: Due December 26
  • Mar/Apr 2023: Due February 27
  • May/June 2023: Due April 24
  • July/Aug 2023: Due June 26
Newsletter Submission Guidelines

  • Pharmacists, pharmacy technicians, and pharmacy students in Missouri are eligible to submit content for publication in the MSHP Newsletter. Student submissions need to include pharmacist oversight.
  • Submit content to the current Newsletter Committee Chair on or before the established deadlines.
  • CE and Featured Clinical Topics must be approved by the Newsletter Committee Chair in advance of article submission, to prevent duplicates. Duplicate articles submitted without advanced approval may not be published.
  • Recommended length of submissions for committee, affiliate, college/schools of pharmacy, and student chapter reports is half to one page in length.
  • Recommended length of submissions for featured clinical topics is 1 to 2 pages, without references.
  • Recommended length of CE articles is individualized, based on the amount of CE provided.
  • Recommended length of submission for other categories is 1 to 2 pages.
MSHP Board of Directors & Committee Chairs
2022-2023 Board Members

President:

President-Elect:

Immediate Past President: 

Secretary: Becca Nolen

Treasurer: Kristin Peterson
2022-2023 Committee Chairs

Vendor Relations Board Liaison:

Membership Committee:

Public Policy Committee:

Newsletter Committee:

Education and Programming:

Website & Social Media:
Questions & Comments
If you have any questions, comments, or wish to submit an article to for MSHP Newsletter, please contact the Newsletter Committee Chair (Sara Lingow) or another Newsletter Committee member.

2021-2022 MSHP Newsletter Committee Members
Sara Lingow, PharmD, BCACP (Chair) 
Ulyana Kucherepa, PharmD (Vice-Chair) 
Laura Challen, PharmD, MBA, BCPS, BCACP
Hannah Pope, PharmD, BCPS
Gabrielle Gibson, PharmD, BCPS, BCCCP
Haley Johnson, PharmD, BCPS
Lauren Hetzler, PharmD
Melissa Green, PharmD, BCPS
Emily Shor, PharmD, BCPS
Sarah Cook, PharmD, BCPS

Connect with Us on Social Media